RALEIGH – Solar Biotech, Inc., has raised $2 million in debt from a single investor of a possible $4 million, according to an SEC filing.

The company, founded in 2019 by Alex Berlin, who also serves as the CEO, “provides contract technology development and manufacturing services to industrial biotechnology players, in particular, to the synthetic biology emerging industry,” according to Berlin’s LinkedIn profile.  The company has three open jobs, according to LinkedIn, and also operates in Norton, Virginia.

According to the SEC filing, the company generates between $5 million and $25 million in revenue, and the fundraising includes a security to be acquired upon exercise of option, warrant, or other right to acquire security.  An estimated $150,000 of the gross proceeds will be used for payments to Berlin, according to the filing, which was signed earlier this week.

Berlin declined to comment further on the fundraising process or how the funds will be utilized.

“We’re just focused on working really hard,” he said. “Scaling up our technology for clients.”

According to the company’s LinkedIn page, it uses what is calls “SynBio Hyperintegration Algorithms,” or SHAs, that deliver customized modular plant architectures, or “BioNodes” for each synthetic biology product.